Medscape
BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the phase 3, randomized, double-blind, placebo-controlled ASTRO study. Importantly, the study also showed that subcutaneous induction is consistent with intravenous (IV) induction of guselkumab in UC…
Read More
Subcutaneous Guselkumab Proves Efficacious for IBD
Elroy Roberie
07:19
BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the phase 3, randomized, double-blind, placebo-controlled ASTRO study. Importantly, the study also showed that subcutaneous induction is consistent with intravenous (IV) induction of guselkumab in UC…
